Initial Management of Small-Cell Lung Cancer (limited- and Extensive-Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy: A Systematic Review
Author(s) -
A. Sun,
Lisa Durocher-Allen,
Peter Ellis,
Yee Ung,
John R. Goffin,
Kevin Ramchandar,
Gail Darling
Publication year - 2019
Publication title -
current oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.053
H-Index - 51
eISSN - 1718-7729
pISSN - 1198-0052
DOI - 10.3747/co.26.4481
Subject(s) - medicine , etoposide , chemotherapy , radiation therapy , cisplatin , oncology , stage (stratigraphy) , carboplatin , lung cancer , paleontology , biology
Patients with limited-stage (ls) or extensive-stage (es) small-cell lung cancer (sclc) are commonly given platinum-based chemotherapy as first-line treatment. Standard chemotherapy for patients with ls sclc includes a platinum agent such as cisplatin combined with the non-platinum agent etoposide. The objective of the present systematic review was to investigate the efficacy of adding radiotherapy to chemotherapy in patients with es sclc and to determine the appropriate timing, dose, and schedule of chemotherapy or radiation for patients with sclc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom